Chicago, IL – October 14, 2024 – Stocks in this week’s article are Atour Lifestyle Holdings Ltd. ATAT, Vertiv Holdings Co. VRT, Corcept Therapeutics Inc. CORT, Qifu Technology Inc. QFIN and ADMA Biologics Inc. ADMA.
5 Stocks with Recent Price Strength Amid October Volatility
October generally remains volatile on Wall Street. This year, volatility has gripped in U.S. stock markets from the beginning of this month. October's volatility is expected to persist due to a better-than-expected jobs data for September, expectations of a Fed rate cut in a gradual fashion rather than more aggressive way, a jump in the yield of the benchmark 10-Year Treasury Note, intensified geopolitical conflict in the Middle East and the upcoming U.S. Presidential election on Nov. 5.
Consequently, a handful of stocks have shown price strength. We have primarily targeted stocks that have recently been on a bull run. Such stocks have a high chance of carrying the momentum forward.
Five such stocks are - Atour Lifestyle Holdings Ltd., Vertiv Holdings Co., Corcept Therapeutics Inc., Qifu Technology Inc. and ADMA Biologics Inc..
If a stock is continuously witnessing an uptrend, there must be a solid reason or it would have probably crashed. So, looking at stocks capable of beating the benchmark that they have set for themselves seems rational.
However, recent price strength alone cannot create magic. Therefore, other relevant parameters are needed to create a successful investment strategy.
Here's how you should create the screen to shortlist the current as well as the potential winners.
Let's discuss five out of these 16 stocks:
Atour Lifestyle Holdings Ltd. develops lifestyle brands around hotel offerings in the People's Republic of China. ATAT provides hotel management services, including day-to-day management services of the hotels for the franchisees; and sells hotel supplies and other products.
ATAT also offers retail management service; investment management service; financial information service management; property management services; and software and technology services, as well as operates a travel agency.
The stock price of Atour Lifestyle Holdings has jumped 39% in the past four weeks. The company has expected earnings growth of 32.6% for the current year. The Zacks Consensus Estimate for the current year has improved 10.9% over the last 60 days.
Vertiv Holdings Co. designs, manufactures, and services critical digital infrastructure technologies and life cycle services for data centers, communication networks, and commercial and industrial environments in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. VRT offers hardware, software, analytics and ongoing services.
The stock price of Vertiv Holdings has climbed 31.2% in the past four weeks. It has an expected earnings growth rate of 45.8% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 6.2% over the last 90 days.
Corcept Therapeutics Inc. is engaged in the discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. CORT offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome, and for those who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
CORT is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome, treatment for adrenal cancer and cortisol excess, which is in phase 1b clinical trial, treatment for prostate cancer which is in phase II clinical trial and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
The stock price of Corcept Therapeutics has surged 29.2% in the past four weeks. It has an expected earnings growth rate of 19.2% for the current year. The Zacks Consensus Estimate for current-year earnings improved 1.8% over the last 30 days.
Qifu Technology Inc. operates as a credit-tech platform under the 360 Jietiao brand in the People's Republic of China. QFIN provides credit-driven services that match borrowers with financial institutions to conduct customer acquisition, initial and credit screening, advanced risk assessment, credit assessment, fund matching, and other post-facilitation services and platform services. QFIN also offers e-commerce loans, enterprise loans, and invoice loans to SME owners. QFIN serves financial institutions, consumers, and small- and micro-enterprises.
The stock price of Qifu Technology has appreciated 25% in the past four weeks. The company has expected earnings growth of 38% for the current year. The Zacks Consensus Estimate for the current year has improved 2.8% over the last 30 days.
ADMA Biologics Inc. is a specialty immune globulin company. ADMA develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases.
ADMA's target patient populations include immune-compromised individuals suffering from an underlying immune deficiency disease or are immune-suppressed for medical reasons. ADMA's lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease.
The stock price of ADMA Biologics has advanced 20.2% in the past four weeks. It has an expected earnings growth rate of 29.6% for next year. The Zacks Consensus Estimate for next-year earnings has improved 8.5% over the last 60 days.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2349113/5-stocks-with-recent-price-strength-amid-october-volatility
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
